{
  "id": 10823976,
  "title": "Kura Oncology CCO Brian Powl sells over $345k in company stock",
  "url": "https://urgent.news/2026/09/30/kura-oncology-cco-brian-powl-sells-over-345k-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T01:16:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/kura-oncology-cco-brian-powl-sells-over-345k-in-company-stock-93CH-4923966"
  },
  "original_language": "en",
  "account": "Kura Oncology's Chief Commercial Officer, Brian Powl, recently sold a substantial amount of company stock, totaling $345,034. This stock sale occurred on September 28 and 29, 2026, during which Powl traded 32,450 shares of the company's common stock. The stock was valued at around $10.81 per share at the time, resulting in a market capitalization of $943.87 million. Despite a slight 2.1% decline in stock price over the past week, the shares have increased by 32.9% over the last six months. On September 28, Powl sold 9,020 shares at $10.4973 per share, valued at $94,685. This sale was made to cover taxes from the vesting of restricted stock units received earlier. Later that same day, he sold another 8,000 shares acquired upon the vesting of these units, this time at a weighted average price of $10.5622 per share. On September 29, Powl sold 15,430 additional shares, also acquired through the vesting of restricted stock units, at a weighted average price of $10.7487 per share. These transactions were all conducted under a pre-approved trading plan. After these reported sales, Powl still holds 136,819 shares of Kura Oncology common stock. Kura Oncology's stock is currently trading slightly above its Fair Value, according to InvestingPro analysis.",
  "summary": null,
  "key_points": [
    "Kura Oncology CCO Brian Powl sold $345,034 worth of company stock.",
    "Powl traded 32,450 shares at $10.81 per share on September 28-29, 2026.",
    "Sales covered taxes from restricted stock unit vesting."
  ],
  "editors_take": "The sale of over $345,000 in Kura Oncology stock by its Chief Commercial Officer, Brian Powl, to cover taxes from vested restricted stock units does not appear to signal a loss of confidence in the company.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Kura Oncology COO Kathleen Ford sells $111,930 in company stock",
        "url": "https://urgent.news/2026/09/30/kura-oncology-coo-kathleen-ford-sells-111-930-in-company-stock",
        "published": "2026-09-30T01:01:25.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}